SmarTrend identified a Downtrend for Celgene Corp (NASDAQ:CELG) on October 13th, 2017 at $137.01. In approximately 2 months, Celgene Corp has returned 22.39% as of today's recent price of $106.33. In the past 52 weeks, shares of …
As the broader market rallied on Tuesday on the back of hopeful rhetoric around tax reform, the healthcare sector happily participated. The biotechnology subgroup of stocks also flocked higher, leaving plenty of so-called “bullish reversals” …
Shares of the Celgene Corporation rose 5.9 percent yesterday after regulators approved the company's Revlimid capsule for a rare blood cancer, a treatment that will cost pharmacies $215 to $225 a pill. The Food and Drug Administration …
Celgene Corporation's (NASDAQ:CELG) stock were down more than 5% in premarket trade following news of a drug development disappointment. In after-hours on Thursday, the pharmaceutical firm announced it would not take a …
If you're looking for a smart stock to buy right now, look no further than Celgene (NASDAQ: CELG). The big biotech has hit a rough patch lately, with a major clinical setback, missing third-quarter revenue expectations, and lowering its full …
Biotech stocks and the related ETFs have been the star performers this year despite some temporary glitches and …
The offer of $87 per share for the 90 percent of Juno that Celgene does not own sent Juno's stock soaring 27 percent to $86.31 in premarket trading. Shares of Celgene fell 1 percent to $101.60. The two companies said the deal, agreed by …
BOSTON (Reuters) - Shares of biotechnology company Celgene Inc. (CELG.O) rose more than 3 percent on Tuesday amid speculation that a clinical trial of its cancer drug Revlimid is being stopped early because the results are so …
SUMMIT, N.J. (AP) — Biopharmaceutical company Celgene is buying the remainder of Juno Therapeutics Inc. that it doesn't already own in a deal valued at about $9 billion, which will help it develop medicines for patients with incurable …
tdn1mon
At $95.64, the stock has room to fall short-term, even if the positive trends remain in place: “Correction support” comes into play at the $89.70-$91.30 range and the long-term uptrend line comes into play at around $83. Technicians still call …